Latest Santen Pharmaceutica (SNPHF) Headlines G
Post# of 3
Posted On: 03/11/2014 10:14:49 AM
Latest Santen Pharmaceutica (SNPHF) Headlines
Global Ophthalmology Drugs And Devices (Diagnostic & Surgical) Market Report 2013-2017
M2 - Thu Nov 21, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/384qp6/ophthalmology) has announced the addition of the "Global Ophthalmology Drugs And Devices (Diagnostic & Surgical) Market Report 2013-2017" report to their offering. The ophthalmology drugs and devices market is divided into four major segments, namely, surgical devices, diagnostic and monitoring devices, vision care, and drugs. The devices market is divided into applications like surgery and diagnostics. Drugs market is classified into existing treatment drugs and drugs in pipeline and the vision care market is segmented into spectacles and contact lenses. The total market is forecasted till 2017. This market is also considered by formulation types such as capsules, gels, eye drops, ointment, and eye solutions. Advancements in technologies, high prevalence rates of refractive error, cataract, and glaucoma, increasing demand for the diagnostic procedures and low compliance with pharmaceuticals will propel the devices market. However, lack of awareness of diseases like glaucoma hinders the growth of this market. The drugs market will grow at a slower pace mainly due to the combined effect of loss of patent protection for several drugs and drying pipeline. The geographies covered in this study are North America, Europe, Asia-Pacific (APAC) and Rest of the world (RoW). North America is the largest market for ophthalmology drugs and devices, followed by Europe and Asia. North America and Europe is expected to grow at a slower pace, primarily due to the economic slowdown and saturation in these markets. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Ophthalmology Devices Market 5 Global Ophthalmology Drug Market 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles Companies Mentioned - Abbott Laboratories - Alcon, Inc. - Allergan, Inc - Bausch & Lomb, Inc. - Carl Zeiss Meditec Ag - Ellex Medical Lasers Limited - Essilor International S.A - Hoya Corporation - Iridex Corporation - Johnson & Johnson - Merck & Co., Inc - Nidek Co., Limited - Novagali Pharma S.A - Novartis Ag - Pfizer, Inc - Roche Holding Ag - Santen Pharmaceutical Co., Ltd. - Staar Surgical Company - Topcon Corporation - Ziemer Group Holding Ag For more information visit http://www.researchandmarkets.com/research/38...thalmology
Diabetic Macular Edema - Pipeline Review, H2 2013 Gives a Snapshot of the Global Therapeutic Scenario for Diabetic Macular Edema
M2 - Tue Nov 05, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/jcpdr7/diabetic_macular) has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Diabetic Macular Edema - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema. Diabetic Macular Edema - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Macular Edema pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - GlaxoSmithKline plc - Quark Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Lux Biosciences, Inc. - Novagali Pharma SA - Astellas Pharma Inc. - TheraKine Inc. - iCo Therapeutics Inc. - NicOx SA - Regeneron Pharmaceuticals, Inc. - ThromboGenics NV - Foamix Ltd. - Molecular Partners AG - Senju Pharmaceutical Co., Ltd. - Pfenex Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - Ampio Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/jc...ic_macular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Keratitis Clinical Trials Review Report - H2, 2013
M2 - Wed Oct 16, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x4l6gl/keratitis_global) has announced the addition of the "Keratitis Global Clinical Trials Review, H2, 2013" report to their offering. Keratitis Global Clinical Trials Review, H2, 2013" provides data on the Keratitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Keratitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Keratitis. Reasons to buy: - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Keratitis Therapeutics Clinical Trials - Adapt Produtos Oftalmologicos Ltda - Ajanta Pharma Limited - Alcon Research Ltd. - Allergan, Inc. - Bausch & Lomb Incorporated - Dompe S.p.A. - Les Laboratoires Servier SAS - Menarini International O.L.S.A - Novartis AG - Santen Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/x4...tis_global
Macular Edema - Pipeline Review, H2 2013
M2 - Mon Oct 07, 4:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xwnkkw/macular_edema) has announced the addition of the "Macular Edema - Pipeline Review, H2 2013" report to their offering. 'Macular Edema - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Edema. Scope - A snapshot of the global therapeutic scenario for Macular Edema. - A review of the Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Edema pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Macular Edema. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Macular Edema pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned F. Hoffmann-La Roche Ltd. Allergan, Inc. Santen Pharmaceutical Co., Ltd. Regeneron Pharmaceuticals, Inc. Promedior, Inc. Inotek Pharmaceuticals Corporation Taiwan Liposome Company For more information visit http://www.researchandmarkets.com/research/xw...ular_edema About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Glaucoma - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2kcjq/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2013" report to their offering. 'Glaucoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glaucoma. Scope - A snapshot of the global therapeutic scenario for Glaucoma. - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Glaucoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. QLT Inc. Advanced Cell Technology, Inc. Quark Pharmaceuticals, Inc. Santen Pharmaceutical Co., Ltd. Oxford BioMedica plc Sylentis RetinaPharma Technologies, Inc. Novagali Pharma SA Kowa Company, Ltd. Merz GmbH & Co. KGaA Ono Pharmaceutical Co., Ltd. Pfizer Inc. Sun Pharmaceutical Industries Limited InSite Vision Incorporated Can-Fite BioPharma Ltd. NicOx SA ACADIA Pharmaceuticals Inc. Lexicon Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/l2kcjq/glaucoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Uveitis - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cbbpd2/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2013" report to their offering. 'Uveitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Uveitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uveitis. Scope - A snapshot of the global therapeutic scenario for Uveitis. - A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Uveitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Uveitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Alcon, Inc. pSivida Corp. Inovio Biomedical Corporation Santen Pharmaceutical Co., Ltd. Apitope International NV Novartis AG Isotechnika Pharma Inc. TheraKine Inc. Enzo Biochem, Inc. Can-Fite BioPharma Ltd. Regeneron Pharmaceuticals, Inc. XOMA Ltd. Hanall Pharmaceutical Co., Ltd. Artielle ImmunoTherapeutics, Inc. ProtAffin Biotechnologie AG Endocyte, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/cbbpd2/uveitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Rheumatoid Arthritis Report - Drug Pipeline Review
M2 - Tue Sep 03, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xw6rsc/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2013" report to their offering. 'Rheumatoid Arthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. Scope - A snapshot of the global therapeutic scenario for Rheumatoid Arthritis. - A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Featured - Alcon, Inc. - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Amgen Inc. - Antares Pharma, Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Inovio Biomedical Corporation - MedImmune LLC - Isis Pharmaceuticals, Inc. - Biotest AG - Merck & Co., Inc. - Santen Pharmaceutical Co., Ltd. - Ablynx - Emergent BioSolutions Inc. - Novo Nordisk A/S - Infinity Pharmaceuticals, Inc. - Albany Molecular Research, Inc. - Plexxikon Inc. - ViaCord - arGentis Pharmaceuticals, LLC - Reliance Life Sciences Pvt. Ltd. - MediGene AG For more information visit http://www.researchandmarkets.com/research/xw6rsc/rheumatoid
Ocular Hypertension - Pipeline Review, H2 2012
M2 - Thu Aug 01, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hswq4v/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. It also provides information on the therapeutic development for Ocular Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ocular Hypertension. The information is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Ocular Hypertension. - A review of the Ocular Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ocular Hypertension pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Ocular Hypertension Overview Therapeutics Development An Overview of Pipeline Products for Ocular Hypertension Companies Involved in Ocular Hypertension Therapeutics Development Ocular Hypertension - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Aerie Pharmaceuticals, Inc - Alcon, Inc - Allergan, Inc - Asahi Kasei Pharma - Bausch & Lomb Incorporated - F. Hoffmann-La Roche Ltd - Inotek Pharmaceuticals Corporation - Kowa Company, Ltd - LABORATOIRES THEA - Novagali Pharma SA - Ono Pharmaceutical Co - QLT Inc - Santen Incorporated - Santen Pharmaceutical Co., Ltd - Senju Pharmaceutical Co - Sun Pharmaceutical Industries Limited - Sylentis For more information visit http://www.researchandmarkets.com/research/hswq4v/ocular
Allergic Conjunctivitis - Pipeline Review, H2 2012
M2 - Fri Jul 26, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bx8lxr/allergic) has announced the addition of the "Allergic Conjunctivitis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Allergic Conjunctivitis. - A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Allergic Conjunctivitis Overview Therapeutics Development An Overview of Pipeline Products for Allergic Conjunctivitis Allergic Conjunctivitis Therapeutics under Development by Companies Allergic Conjunctivitis Therapeutics under Investigation by Universities/Institutes Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Pre-Clinical Stage Products Comparative Analysis Allergic Conjunctivitis Therapeutics - Products under Development by Companies Allergic Conjunctivitis Therapeutics - Products under Investigation by Universities/Institutes Companies Involved in Allergic Conjunctivitis Therapeutics Development Bausch & Lomb Incorporated Allergan, Inc. Bayer HealthCare AG Santen Pharmaceutical Co., Ltd Sun Pharmaceutical Industries Limited Fovea Pharmaceuticals SA LABORATOIRES THEA Oxagen Limited Morria Biopharmaceuticals Plc Drug Profiles Allergic Conjunctivitis Therapeutics - Drug Profile Updates Allergic Conjunctivitis Therapeutics - Discontinued Products Allergic Conjunctivitis Therapeutics - Dormant Products Allergic Conjunctivitis - Product Development Milestones Featured News & Press Releases Appendix For more information visit http://www.researchandmarkets.com/research/bx8lxr/allergic
Conjunctivitis - Pipeline Review, H2 2012
M2 - Thu Jul 11, 11:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3z578/conjunctivitis) has announced the addition of the "Conjunctivitis - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the Conjunctivitis therapeutic pipeline. This report provides information on the therapeutic development for Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Conjunctivitis. 'Conjunctivitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Conjunctivitis Overview Therapeutics Development An Overview o
Discontinuance and Abolition of Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)
GlobeNewswire - Fri Apr 26, 6:01AM CDT
Santen Pharmaceutical Co., Ltd. (the "Company") announces that at a meeting held today, its Board of Directors resolved to discontinue and abolish the "Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)" of the Company as of the close of the annual general meeting of the shareholders for the 101st fiscal year to be held on June 25, 2013 (the "Annual General Meeting of the Shareholders"), which were introduced based on the approval of the shareholders at the annual general meeting of the shareholders held on June 26, 2007, and partially revised and approved to be continued at the annual general meeting of the shareholders held on June 23, 2010 (the revised plan shall be referred to as the "Plan"). The Plan will remain effective until the close of the Annual General Meeting of the Shareholders.
Santen Ltd. Announces Change in Management Structure for U.S. Subsidiary Organization
Business Wire - Tue Mar 12, 8:00AM CDT
Santen Pharmaceutical Co., Ltd., (Osaka, Japan, Tokyo Stock Exchange: 4536) Japan's leading ophthalmic pharmaceutical company, announced today the appointment of Naveed Shams, M.D., Ph.D. as the President and CEO of Santen Inc., and Chief Scientific Officer of Santen Ltd. Prior to this new appointment, Dr. Shams was Vice President and Head of Global Clinical Development and Medical Affairs (GCD&MA). Dr. Shams received his medical degree from Dow Medical College in Karachi, Pakistan, and his Ph.D. in Microbiology & Immunology from the University of South Carolina. After completing a fellowship in Cornea and External Disease at the Schepens Eye Research Institute & Department of Ophthalmology, Harvard Medical School, he served on the Research Faculty in the Department. Dr. Shams joined Santen Inc. almost 3 years ago. His industry experience spans 19 years across multiple therapeutic areas and includes tenures with Genen
Santen Pharmaceutical Co., Ltd. and Clearside Biomedical, Inc. Enter into Financing and Research Collaboration Agreements for Posterior Ocular Disease
Business Wire - Thu Jan 31, 7:00AM CST
Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd. (Osaka, Japan, Ticker Code 4536JP), and Clearside Biomedical, Inc. announced today that Santen Ltd., the parent company of Santen Inc., has made an investment in Clearside Biomedical Inc. and has also entered into a research collaboration agreement for posterior ocular diseases. Santen will join with other investors to fund an additional $7.9 million for continued development of CLS1001 into pivotal testing and to further Clearside Biomedical's pipeline in ocular choroidal neovascularization and inflammatory diseases of the posterior segment. Santen, along with new investor Mountain Group Capital and its affiliates join current investors Hatteras Venture Partners, Georgia Research Alliance Venture Fund, and Kenan Flagler Business School Private Equity Fund.
Global Ophthalmology Drugs And Devices (Diagnostic & Surgical) Market Report 2013-2017
M2 - Thu Nov 21, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/384qp6/ophthalmology) has announced the addition of the "Global Ophthalmology Drugs And Devices (Diagnostic & Surgical) Market Report 2013-2017" report to their offering. The ophthalmology drugs and devices market is divided into four major segments, namely, surgical devices, diagnostic and monitoring devices, vision care, and drugs. The devices market is divided into applications like surgery and diagnostics. Drugs market is classified into existing treatment drugs and drugs in pipeline and the vision care market is segmented into spectacles and contact lenses. The total market is forecasted till 2017. This market is also considered by formulation types such as capsules, gels, eye drops, ointment, and eye solutions. Advancements in technologies, high prevalence rates of refractive error, cataract, and glaucoma, increasing demand for the diagnostic procedures and low compliance with pharmaceuticals will propel the devices market. However, lack of awareness of diseases like glaucoma hinders the growth of this market. The drugs market will grow at a slower pace mainly due to the combined effect of loss of patent protection for several drugs and drying pipeline. The geographies covered in this study are North America, Europe, Asia-Pacific (APAC) and Rest of the world (RoW). North America is the largest market for ophthalmology drugs and devices, followed by Europe and Asia. North America and Europe is expected to grow at a slower pace, primarily due to the economic slowdown and saturation in these markets. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Ophthalmology Devices Market 5 Global Ophthalmology Drug Market 6 Geographic Analysis 7 Competitive Landscape 8 Company Profiles Companies Mentioned - Abbott Laboratories - Alcon, Inc. - Allergan, Inc - Bausch & Lomb, Inc. - Carl Zeiss Meditec Ag - Ellex Medical Lasers Limited - Essilor International S.A - Hoya Corporation - Iridex Corporation - Johnson & Johnson - Merck & Co., Inc - Nidek Co., Limited - Novagali Pharma S.A - Novartis Ag - Pfizer, Inc - Roche Holding Ag - Santen Pharmaceutical Co., Ltd. - Staar Surgical Company - Topcon Corporation - Ziemer Group Holding Ag For more information visit http://www.researchandmarkets.com/research/38...thalmology
Diabetic Macular Edema - Pipeline Review, H2 2013 Gives a Snapshot of the Global Therapeutic Scenario for Diabetic Macular Edema
M2 - Tue Nov 05, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/jcpdr7/diabetic_macular) has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Diabetic Macular Edema - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema. Diabetic Macular Edema - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Macular Edema pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - GlaxoSmithKline plc - Quark Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Lux Biosciences, Inc. - Novagali Pharma SA - Astellas Pharma Inc. - TheraKine Inc. - iCo Therapeutics Inc. - NicOx SA - Regeneron Pharmaceuticals, Inc. - ThromboGenics NV - Foamix Ltd. - Molecular Partners AG - Senju Pharmaceutical Co., Ltd. - Pfenex Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - Ampio Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/jc...ic_macular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Keratitis Clinical Trials Review Report - H2, 2013
M2 - Wed Oct 16, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x4l6gl/keratitis_global) has announced the addition of the "Keratitis Global Clinical Trials Review, H2, 2013" report to their offering. Keratitis Global Clinical Trials Review, H2, 2013" provides data on the Keratitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Keratitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Keratitis. Reasons to buy: - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Keratitis Therapeutics Clinical Trials - Adapt Produtos Oftalmologicos Ltda - Ajanta Pharma Limited - Alcon Research Ltd. - Allergan, Inc. - Bausch & Lomb Incorporated - Dompe S.p.A. - Les Laboratoires Servier SAS - Menarini International O.L.S.A - Novartis AG - Santen Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/x4...tis_global
Macular Edema - Pipeline Review, H2 2013
M2 - Mon Oct 07, 4:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xwnkkw/macular_edema) has announced the addition of the "Macular Edema - Pipeline Review, H2 2013" report to their offering. 'Macular Edema - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Edema. Scope - A snapshot of the global therapeutic scenario for Macular Edema. - A review of the Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Edema pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Macular Edema. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Macular Edema pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned F. Hoffmann-La Roche Ltd. Allergan, Inc. Santen Pharmaceutical Co., Ltd. Regeneron Pharmaceuticals, Inc. Promedior, Inc. Inotek Pharmaceuticals Corporation Taiwan Liposome Company For more information visit http://www.researchandmarkets.com/research/xw...ular_edema About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Glaucoma - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2kcjq/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2013" report to their offering. 'Glaucoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glaucoma. Scope - A snapshot of the global therapeutic scenario for Glaucoma. - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Glaucoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. QLT Inc. Advanced Cell Technology, Inc. Quark Pharmaceuticals, Inc. Santen Pharmaceutical Co., Ltd. Oxford BioMedica plc Sylentis RetinaPharma Technologies, Inc. Novagali Pharma SA Kowa Company, Ltd. Merz GmbH & Co. KGaA Ono Pharmaceutical Co., Ltd. Pfizer Inc. Sun Pharmaceutical Industries Limited InSite Vision Incorporated Can-Fite BioPharma Ltd. NicOx SA ACADIA Pharmaceuticals Inc. Lexicon Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/l2kcjq/glaucoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Uveitis - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cbbpd2/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2013" report to their offering. 'Uveitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Uveitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uveitis. Scope - A snapshot of the global therapeutic scenario for Uveitis. - A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Uveitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Uveitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Alcon, Inc. pSivida Corp. Inovio Biomedical Corporation Santen Pharmaceutical Co., Ltd. Apitope International NV Novartis AG Isotechnika Pharma Inc. TheraKine Inc. Enzo Biochem, Inc. Can-Fite BioPharma Ltd. Regeneron Pharmaceuticals, Inc. XOMA Ltd. Hanall Pharmaceutical Co., Ltd. Artielle ImmunoTherapeutics, Inc. ProtAffin Biotechnologie AG Endocyte, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/cbbpd2/uveitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Rheumatoid Arthritis Report - Drug Pipeline Review
M2 - Tue Sep 03, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xw6rsc/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2013" report to their offering. 'Rheumatoid Arthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. Scope - A snapshot of the global therapeutic scenario for Rheumatoid Arthritis. - A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Featured - Alcon, Inc. - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Amgen Inc. - Antares Pharma, Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Inovio Biomedical Corporation - MedImmune LLC - Isis Pharmaceuticals, Inc. - Biotest AG - Merck & Co., Inc. - Santen Pharmaceutical Co., Ltd. - Ablynx - Emergent BioSolutions Inc. - Novo Nordisk A/S - Infinity Pharmaceuticals, Inc. - Albany Molecular Research, Inc. - Plexxikon Inc. - ViaCord - arGentis Pharmaceuticals, LLC - Reliance Life Sciences Pvt. Ltd. - MediGene AG For more information visit http://www.researchandmarkets.com/research/xw6rsc/rheumatoid
Ocular Hypertension - Pipeline Review, H2 2012
M2 - Thu Aug 01, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hswq4v/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. It also provides information on the therapeutic development for Ocular Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ocular Hypertension. The information is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Ocular Hypertension. - A review of the Ocular Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ocular Hypertension pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Ocular Hypertension Overview Therapeutics Development An Overview of Pipeline Products for Ocular Hypertension Companies Involved in Ocular Hypertension Therapeutics Development Ocular Hypertension - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Aerie Pharmaceuticals, Inc - Alcon, Inc - Allergan, Inc - Asahi Kasei Pharma - Bausch & Lomb Incorporated - F. Hoffmann-La Roche Ltd - Inotek Pharmaceuticals Corporation - Kowa Company, Ltd - LABORATOIRES THEA - Novagali Pharma SA - Ono Pharmaceutical Co - QLT Inc - Santen Incorporated - Santen Pharmaceutical Co., Ltd - Senju Pharmaceutical Co - Sun Pharmaceutical Industries Limited - Sylentis For more information visit http://www.researchandmarkets.com/research/hswq4v/ocular
Allergic Conjunctivitis - Pipeline Review, H2 2012
M2 - Fri Jul 26, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bx8lxr/allergic) has announced the addition of the "Allergic Conjunctivitis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Allergic Conjunctivitis. - A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Allergic Conjunctivitis Overview Therapeutics Development An Overview of Pipeline Products for Allergic Conjunctivitis Allergic Conjunctivitis Therapeutics under Development by Companies Allergic Conjunctivitis Therapeutics under Investigation by Universities/Institutes Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Pre-Clinical Stage Products Comparative Analysis Allergic Conjunctivitis Therapeutics - Products under Development by Companies Allergic Conjunctivitis Therapeutics - Products under Investigation by Universities/Institutes Companies Involved in Allergic Conjunctivitis Therapeutics Development Bausch & Lomb Incorporated Allergan, Inc. Bayer HealthCare AG Santen Pharmaceutical Co., Ltd Sun Pharmaceutical Industries Limited Fovea Pharmaceuticals SA LABORATOIRES THEA Oxagen Limited Morria Biopharmaceuticals Plc Drug Profiles Allergic Conjunctivitis Therapeutics - Drug Profile Updates Allergic Conjunctivitis Therapeutics - Discontinued Products Allergic Conjunctivitis Therapeutics - Dormant Products Allergic Conjunctivitis - Product Development Milestones Featured News & Press Releases Appendix For more information visit http://www.researchandmarkets.com/research/bx8lxr/allergic
Conjunctivitis - Pipeline Review, H2 2012
M2 - Thu Jul 11, 11:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3z578/conjunctivitis) has announced the addition of the "Conjunctivitis - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the Conjunctivitis therapeutic pipeline. This report provides information on the therapeutic development for Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Conjunctivitis. 'Conjunctivitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Conjunctivitis Overview Therapeutics Development An Overview o
Discontinuance and Abolition of Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)
GlobeNewswire - Fri Apr 26, 6:01AM CDT
Santen Pharmaceutical Co., Ltd. (the "Company") announces that at a meeting held today, its Board of Directors resolved to discontinue and abolish the "Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)" of the Company as of the close of the annual general meeting of the shareholders for the 101st fiscal year to be held on June 25, 2013 (the "Annual General Meeting of the Shareholders"), which were introduced based on the approval of the shareholders at the annual general meeting of the shareholders held on June 26, 2007, and partially revised and approved to be continued at the annual general meeting of the shareholders held on June 23, 2010 (the revised plan shall be referred to as the "Plan"). The Plan will remain effective until the close of the Annual General Meeting of the Shareholders.
Santen Ltd. Announces Change in Management Structure for U.S. Subsidiary Organization
Business Wire - Tue Mar 12, 8:00AM CDT
Santen Pharmaceutical Co., Ltd., (Osaka, Japan, Tokyo Stock Exchange: 4536) Japan's leading ophthalmic pharmaceutical company, announced today the appointment of Naveed Shams, M.D., Ph.D. as the President and CEO of Santen Inc., and Chief Scientific Officer of Santen Ltd. Prior to this new appointment, Dr. Shams was Vice President and Head of Global Clinical Development and Medical Affairs (GCD&MA). Dr. Shams received his medical degree from Dow Medical College in Karachi, Pakistan, and his Ph.D. in Microbiology & Immunology from the University of South Carolina. After completing a fellowship in Cornea and External Disease at the Schepens Eye Research Institute & Department of Ophthalmology, Harvard Medical School, he served on the Research Faculty in the Department. Dr. Shams joined Santen Inc. almost 3 years ago. His industry experience spans 19 years across multiple therapeutic areas and includes tenures with Genen
Santen Pharmaceutical Co., Ltd. and Clearside Biomedical, Inc. Enter into Financing and Research Collaboration Agreements for Posterior Ocular Disease
Business Wire - Thu Jan 31, 7:00AM CST
Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd. (Osaka, Japan, Ticker Code 4536JP), and Clearside Biomedical, Inc. announced today that Santen Ltd., the parent company of Santen Inc., has made an investment in Clearside Biomedical Inc. and has also entered into a research collaboration agreement for posterior ocular diseases. Santen will join with other investors to fund an additional $7.9 million for continued development of CLS1001 into pivotal testing and to further Clearside Biomedical's pipeline in ocular choroidal neovascularization and inflammatory diseases of the posterior segment. Santen, along with new investor Mountain Group Capital and its affiliates join current investors Hatteras Venture Partners, Georgia Research Alliance Venture Fund, and Kenan Flagler Business School Private Equity Fund.
(0)
(0)Santen Pharmaceutica (SNPHF) Stock Research Links
Scroll down for more posts ▼